TB-CHAMP, VQUIN, and the first effective treatment to prevent multidrug-resistant tuberculosis

TB-CHAMP, VQUIN, and the first effective treatment to prevent multidrug-resistant tuberculosis
In September 2024, the World Health Organization (WHO) released new guidance on preventative treatment for tuberculosis (TB). Thanks to new evidence from two randomised controlled clinical trials, the WHO now recommends that contacts of people with multidrug-resistant TB take six months of daily levofloxacin. In this episode of the Trial Talk podcast, we find out more about the TB-CHAMP and VQUIN trials. We also learn how the teams came together to combine their data and strengthen their evidence, using new statistical methodologies developed at the MRC Clinical Trials Unit at UCL. The episode features interviews with Anneke Hesseling, Principal Investigator for TB-CHAMP, based at Stellenbosch University, and Trinh Duong, based at the MRC CTU at UCL, the trial statistician for TB-CHAMP and lead for the combined data analysis with VQUIN.
Charlotte Hartley
4
9/23/2024
00:32:50
clinical trials, Tuberculosis, clinical research, medical research, Infection, Infections, Infectious Diseases, TB, Global Health
Download